Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?

Breast Cancer

Volumn 18, Issue 4, 2011, Pages 309-313

  Uematsu, Takayoshi ^a   Kasami, Masako ^a   Watanabe, Junichiro ^a   Takahashi, Kaoru ^a   Yamasaki, Seiji ^a   Tanaka, Kumiko ^a   Tadokoro, Yukiko ^a   Ogiya, Akiko ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Breast cancer; Lymphovascular invasion; Neoadjuvant chemotherapy; Pathologic complete response

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER RESISTANCE; CANCER SIZE; CANCER SURGERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; LYMPHOVASCULAR INVASION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR NECROSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 82155187136     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-010-0211-z     Document Type: Article

References (17)

1. P Rastogi SJ Anderson HD Bear CE Geyer MS Kahlenberg A Robidoux, et al. 2008 Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 J Clin Oncol 26 778 785 18258986 10.1200/JCO.2007.15.0235 (Pubitemid 351264391)
2. JR Gralow HJ Burstein W Wood GN Hortobagyi L Gianni G von Minckwitz, et al. 2008 Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operative disease J Clin Oncol 26 814 819 18258991 10.1200/JCO.2007.15.3510 (Pubitemid 351265335)
3. N Tamura T Hasebe N Okada T Houjoh S Akashi-Tanaka C Shimizu, et al. 2009 Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy Cancer Sci 100 1823 1833 19604245 10.1111/j.1349-7006.2009.01264.x 1:CAS:528:DC%2BD1MXht12qs7vF
4. PS Sullivan SK Apple 2009 Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Breast J 15 146 154 19292800 10.1111/j.1524-4741.2009.00689.x
5. R Lauria F Perrone C Carlomagno M De Laurentiis A Morabito C Gallo, et al. 1995 The prognostic value of lymphatic and blood vessel invasion in operative breast cancer Cancer 76 1772 1778 8625046 10.1002/1097-0142(19951115) 76:10<1772::AID-CNCR2820761014>3.0.CO;2-O 1:STN:280:DyaK283itlamsg%3D%3D
6. T Hasebe S Sasaki S Imoto A Ochiai 2001 Characteristics of tumors in lymph vessels play an important role in the tumor progression of invasive ductal carcinoma of the breast: a prospective study Mod Pathol 15 904 913 10.1097/01.MP.0000024289.59262.CE
7. Hasebe T, Okada N, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, et al. Grading system for lymph vessel tumor emboli: significant outcome predictor for invasive ductal carcinoma of the breast. Mod Pathol. 2010. doi: 10.1016/j.humpath.2009.10.015.
8. RL Egan 1982 Multicentric breast carcinomas: clinical-radiographic- pathologic whole organ studies and 10-year survival Cancer 49 1123 1130 6277457 10.1002/1097-0142(19820315)49:6<1123::AID-CNCR2820490610>3.0.CO;2-R 1:STN:280:DyaL387js1Khsw%3D%3D (Pubitemid 12187811)
9. M Kurosumi S Akashi-Tanaka F Akiyama Y Komoike H Mukai, et al. 2008 Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version) Breast Cancer 15 5 7 18224386 10.1007/s12282-007-0016-x
10. ER Fisher S Anderson C Redmond B Fisher 1993 Pathologic findings from the National Surgical Adjuvant Breast Project B-06. 10-year pathologic and clinical prognostic discriminants Cancer 71 2507 2514 8453574 10.1002/1097- 0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0 1:STN:280:DyaK3s3gtFCktw%3D%3D (Pubitemid 23100484)
11. RE Jimenez T Wallis DW Visscher 2001 Centrally necrotizing carcinoma of the breast: a distinct histologic subtype with aggressive clinical behavior Am J Surg Pathol 25 331 337 11224603 10.1097/00000478-200103000-00007 1:STN:280:DC%2BD3M7lvFeqsw%3D%3D (Pubitemid 32174202)
12. RD Leek RJ Landers AL Harris CE Lewis 1999 Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast Br J Cancer 79 991 995 10070902 10.1038/sj.bjc.6690158 1:STN:280:DyaK1M7mvVCmsg%3D%3D (Pubitemid 29082138)
13. M Tubiana-Hulin D Stevens S Lasry JM Guinebretière L Bouita C Cohen-Solal, et al. 2006 Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution Ann Oncol 17 1228 1233 16740599 10.1093/annonc/mdl114 1:STN:280:DC%2BD28vkvVOrsA%3D%3D (Pubitemid 44288213)
14. M Cristofanilli A Gonzalez-Angulo N Sneige SW Kau K Broglio RL Theriault, et al. 2005 Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes J Clin Oncol 23 41 48 15625359 10.1200/JCO.2005.03.111 (Pubitemid 41702621)
15. IK Komenaka MB El-Tamer A Troxel, et al. 2004 Pure mucinous carcinoma of the breast Am J Surg 187 528 532 15041505 10.1016/j.amjsurg.2003.12.039 (Pubitemid 38373811)
16. J Yamaguchi S Akashi-Tanaka T Fukutomi T Kinosita E Iwamoto M Takasugi 2006 A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response Breast Cancer 13 100 103 16518069 10.2325/jbcs.13.100
17. JH Chen B Feig G Agrawal H Yu PM Carpenter RS Mehta, et al. 2008 MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy Cancer 112 17 26 18000804 10.1002/cncr.23130